Canada · Mounjaro
Mounjaro in Canada: real user experiences.
Mounjaro is the brand name of tirzepatide authorized by Health Canada for type 2 diabetes. This page covers the brand-name, prescription side of tirzepatide in Canada. For unbranded experiences see tirzepatide in Canada and the tirzepatide hub.
Mounjaro vs Zepbound vs “research” tirzepatide
- Mounjaro — prescription tirzepatide for adults with type 2 diabetes; Notice of Compliance November 24, 2022 (Health Canada).
- Zepbound — prescription tirzepatide for chronic weight management, listed in the Drug Product Database.
- “Research” tirzepatide— not authorized; Health Canada says “research use only” labelling gives no exemption (details).
Mounjaro vs Ozempic in Canada at a glance
Last reviewed October 15, 2026against Health Canada's Drug Product Database.
| Mounjaro | Ozempic | |
|---|---|---|
| Molecule | Tirzepatide | Semaglutide |
| Targets | GIP and GLP-1 receptors | GLP-1 receptor |
| Maker | Eli Lilly | Novo Nordisk |
| Canadian indication | Type 2 diabetes | Type 2 diabetes |
| Weight-management sister brand | Zepbound | Wegovy |
| Generic in Canada | None (DPD lists only Eli Lilly) | Yes, since April 2026 |
| Side effects | Mounjaro side effects | Ozempic side effects |
Full comparison: Mounjaro vs Ozempic in Canada.
What tirzepatide users report
- 93 published anonymous tirzepatide confessions; 27 mention at least one side effect.
- 10 mention a brand name (Mounjaro or Zepbound) by name.
- Among confessions that state a weight change in pounds, the median reported is 50 lb. Self-reported, unverified.
Most-mentioned side effects (share of tirzepatide confessions):
- Heart rate or palpitations: 11.8% (11)
- Anxiety or panic: 5.4% (5)
- Burping: 4.3% (4)
- Insomnia or poor sleep: 3.2% (3)
- Libido: 3.2% (3)
Counts are phrase mentions in anonymous accounts, not diagnoses or clinical rates. Full breakdown and methodology: tirzepatide side-effects report.
What Canadian writers tell us
Very few published confessions name a Canadian city or province, so we do not report Canada-only statistics. As of October 15, 2026, the handful that do are about retatrutide, an unapproved investigational drug, not about Ozempic, Wegovy, Mounjaro or Zepbound. Three themes come up:
- Large self-reported weight loss over several months, sometimes alongside other unapproved peptides.
- Frustration with cost, which pushes some people toward unregulated online sellers.
- Little understanding of what they are taking (“I don't even understand how it works”).
That last point is the risk Health Canada flags in its April 2026 advisory on peptides bought online. We don't name sellers, prices or doses. If you're in Canada and have used an authorized GLP-1, sharing your experience anonymously from the homepage helps make these pages more useful.
By province and city
Related
Frequently asked questions
- Is Mounjaro approved in Canada?
- Yes. Health Canada issued a Notice of Compliance for Mounjaro (tirzepatide) on November 24, 2022, as a once-weekly prescription treatment for adults with type 2 diabetes.
- What is the difference between Mounjaro and Zepbound in Canada?
- Both contain tirzepatide. Mounjaro is authorized for type 2 diabetes; Zepbound is authorized for chronic weight management in eligible adults. Your prescriber decides which, if either, is appropriate.
- Is Mounjaro the same as tirzepatide?
- Mounjaro is a brand name for tirzepatide made by Eli Lilly. Products sold online as 'research tirzepatide' are not Mounjaro and are not authorized by Health Canada.
- Does this page tell me where to get Mounjaro or how much to take?
- No. We do not publish sourcing, pricing or dosing information. Talk to a licensed Canadian prescriber or pharmacist.
Sources
General information only — not medical, legal or regulatory advice. Peptide Confessions does not sell, source or recommend any product or vendor, and nothing here is dosing guidance. Speak with a licensed Canadian healthcare professional or pharmacist about any medication. Editorial process →